Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Recurring updates describe proof-of-concept work in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combination studies with immunotherapy and other cancer-treatment approaches.
The company also issues news on its broader cancer-treatment platform, including Liora Technologies Europe, radiotherapy technology, patent coverage, trial-site and collaborator activity, capital raises, annual-report highlights, executive and board changes, and investor-conference participation. Its public updates frame LIXT as a clinical-stage pharmaceutical and med-tech issuer focused on new targets for cancer drug development.
Lixte Biotechnology Holdings (Nasdaq: LIXT) announced participation in the Sidoti & Company LLC Virtual Microcap Conference on May 19-20, 2021. CEO John S. Kovach will present on May 20 at 12:15 p.m. ET, discussing the lead drug candidate LB-100, which enhances the efficacy of various anticancer treatments. Lixte's pipeline includes studies for four aggressive cancers, targeting a market exceeding $5 billion. The company aims to leverage its unique IP and lack of clinical competition for LB-100 to capture significant market share.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced participation in the virtual Benzinga Global Small Cap Conference on May 13-14, 2021. CEO John S. Kovach highlighted the potential of their lead drug candidate, LB-100, which targets aggressive cancers like myelodysplastic syndromes and glioblastoma. With a market exceeding $5 billion, Lixte aims to improve cancer treatment through its novel approach, having demonstrated positive preclinical results. The company's pipeline includes three clinical studies and one pharmacology study focused on LB-100.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced on April 13, 2021, the appointment of Gil N Schwartzberg to its Board of Directors following the resignation of Winson Ho. Dr. John S. Kovach, CEO, expressed confidence in Schwartzberg's contributions, noting his experience in guiding the company since its inception. Schwartzberg, former Chairman and CEO of the City of Hope National Medical Center, brings extensive expertise in cancer treatment and research. Lixte continues its focus on developing innovative cancer therapies, notably its lead compound, LB-100.
Lixte Biotechnology Holdings presents promising data on its lead drug candidate, LB-100, which has shown to enhance anti-tumor activity in over 40 preclinical studies without increasing toxicity. The company will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, with CEO John S. Kovach discussing ongoing studies and clinical trials focused on cancers such as myelodysplastic syndrome and glioblastoma. Notably, LB-100 is a first-in-class agent with no known competitors currently in clinical trials.
Lixte Biotechnology Holdings, a clinical-stage drug discovery company, will participate in the 33rd Annual Roth Conference from March 15-17, 2021. CEO John S. Kovach will present their lead compound, LB-100, a first-in-class protein phosphatase inhibitor aimed at enhancing cancer treatments. Currently, LB-100 is being tested in various phases for several cancers, including Myelodysplastic Syndromes and Advanced Soft Tissue Sarcoma. Notably, LB-100 demonstrates potential without increasing toxicity, and there are currently no direct competitors in the market.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed a Registered Direct Offering of $4.19 million in common stock, issuing 1,133,102 shares at $3.70 each. This offering was facilitated by WestPark Capital, which acted as Co-Placement Agent. The shares were issued under a previously filed shelf registration statement with the SEC. This funding aims to bolster Lixte’s clinical-stage drug development focused on cancer treatment and other serious diseases, indicating potential for growth in their innovative therapeutic pipeline.
WallachBeth Capital has successfully completed a $4.19 million Registered Direct Offering for Lixte Biotechnology Holdings (LIXT). A total of 1,133,102 shares of common stock were sold at $3.70 per share. The net proceeds will support working capital and further development of the lead clinical compound LB-100.
The offering was made under a previously filed shelf registration statement. The company is focused on innovative cancer treatment solutions, with LB-100 currently undergoing clinical trials.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced the completion of a registered direct offering, raising approximately $4.19 million through the sale of 1,133,102 shares of common stock at $3.70 per share. The funds will be allocated for working capital and further development of its lead clinical compound, LB-100. WestPark Capital, Inc. and WallachBeth Capital, LLC served as co-placement agents for this transaction.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced a direct offering of 1,133,102 shares of common stock at $3.70 per share, expected to generate approximately $4.19 million in gross proceeds. The funds will support working capital and the development of its lead compound, LB-100, which targets cancer treatment. The transaction is facilitated by WestPark Capital, Inc. and WallachBeth Capital, LLC, with the offering closing on or about March 2, 2021, pending customary conditions. The offering is conducted under a previously effective shelf registration statement.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO John S. Kovach will present the company's first-in-class compound, LB-100, which targets cancer treatment by enhancing the efficacy of standard therapies while minimizing toxicity. LB-100 is currently undergoing clinical studies across four cancer indications: Myelodysplastic Syndromes, Advanced Soft Tissue Sarcoma, Small Cell Lung Cancer, and Glioblastoma Multiforme. A webcast of the presentation will be available on the company's website.